For Philadelphia chromosome–positive (Ph+) ALL, BCR::ABL1 directed tyrosine kinase inhibitors (TKIs) are added to improve durability of responses and survival [7,8]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.